News
Cryoablation added before chemo-immunotherapy in operable lung cancer: a phase 2 trial
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
A phase 2 trial first posted on 2 October 2026 will test whether computed-tomography-guided cryo-thermal ablation added before toripalimab plus platinum chemotherapy improves results in resectable stage IB-IIIB non-small cell lung cancer. West China Hospital is the sponsor; the record lists nine sites in China and a planned enrolment of 40 participants. The registration says the single-arm design will measure efficacy and safety, and that the ablation is intended to make the tumour more responsive to the treatment that follows.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — trial registry record (public domain in the United States); our own summary and a link to the registry record, data as posted on 6 October 2026.